Depression, also referred to as major depressive disorder (MDD), is a major health problem. A number of agents from several chemical classes of drugs are available to treat MDD. Tricyclic antidepressants (TCAs) have been the mainstay of drug therapy for depression since their introduction in the 1960s. However, many patients experience a wide variety of adverse events with these drugs. buy asthma inhaler
The selective serotonin reuptake inhibitors (SSRIs) were introduced two decades later. These agents are reported to have a more favourable safety profile, yet some patients may not tolerate them.
A recent advance has been the introduction of the serotonin norepinephrine reuptake inhibitors (SNRIs), the first of which was venlafaxine . Preliminary clinical results have been promising, and a pharmacoeconomic analysis based on preclinical trials indicated that venlafaxine was cost effective in treating MDD in the United States. However, results were preliminary and relied on unpublished studies; hence, further research is required to define the position of SNRIs in pharmacotherapy.
The purpose of the present research was to summarize the results of published randomized, controlled trials (RCTs) of antidepressants to determine their relative efficacy and toler-ability in treating MDD.